Literature DB >> 32654163

First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.

Araceli Castro Jiménez1, Nuria Navarrete Navarrete1, Alejandro R Gratacós Gómez2, Fernando Florido López1, Rosa García Rodríguez3, Elisa Gómez Torrijos3.   

Abstract

Entities:  

Keywords:  COVID-19; DRESS syndrome; hydroxychloroquine; patch tests

Mesh:

Substances:

Year:  2020        PMID: 32654163      PMCID: PMC7404581          DOI: 10.1111/cod.13657

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


× No keyword cloud information.
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, (formerly known as drug‐induced hypersensitivity syndrome) is an acute, idiosyncratic, and potentially life‐threatening drug reaction, characterized by fever (>38.5°C), skin eruptions, and haematological abnormalities. The most frequently involved drugs are anticonvulsants, sulfonamides, allopurinol, and antibiotics, while hydroxychloroquine has been rarely reported as causative agent.2, 3

CASE REPORT

A 37‐year‐old woman consulted the emergency department for itchy rash, facial edema, and fever (38.5°) developing in the course of 2 days. Physical examination revealed a maculopapular rash, predominantly in the face, periorbital angioedema, and purpuric rash with involvement of the trunk and limbs, but sparing of palms and soles (Figure 1A). Bilateral cervical lymphadenopathy and oral mucosa enanthema were present. The patient had been treated in the previous 2–3 weeks for bilateral pneumonia as manifestation of suspected, but not confirmed, COVID‐19, with hydroxychloroquine 200 mg and lopinavir‐ritonavir 200/50 mg/12 hours and azithromycin 250 mg/day for 5 days. Laboratory tests showed leukocytosis with eosinophilia and elevated transaminases. Abdominal ultrasound was normal, and no atypical lymphocytes were found. Bacterial cultures and viral serologies, including SARS‐CoV‐2, were negative except for IgG for cytomegalovirus, parvovirus B‐19, Epstein–Barr virus, chickenpox, and measles, which were positive. After 8 weeks, patch tests were performed with lopinavir/ritonavir, hydroxychloroquine, and azithromycin (each 20% aq. and pet.), which were positive for hydroxychloroquine on day (D) 4 (Figure 1B). Therefore, DRESS was diagnosed in accordance with RegiSCAR group criteria, and an atypical DRESS according to SCAR‐J's criteria, caused by hydroxychloroquine (Figure 1A and B).
FIGURE 1

(A) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to hydroxychloroquine. Periorbital edema and maculopapular rash on the face. (B) Patch tests with hydroxychloroquine (petrolatum and water) were positive

(A) Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to hydroxychloroquine. Periorbital edema and maculopapular rash on the face. (B) Patch tests with hydroxychloroquine (petrolatum and water) were positive

DISCUSSION

Hydroxychloroquine has been used as an antimalarial. Nowadays, it is used in autoimmune diseases such as lupus and rheumatoid arthritis. The growth of many different viruses can be inhibited in cell culture by chloroquine and hydroxychloroquine, including SARS‐CoV‐2. Therefore, it had been prescribed to our patient with suspected COVID‐19. Hydroxychloroquine is considered to be safe and side‐effects are generally mild and transitory. The most common adverse effect of hydroxychloroquine is a a skin rash; however, in our patient, DRESS syndrome caused by hydroxychloroquine was diagnosed, based on patch testing that proved useful for identifying the causative drug in this patient. In conclusion, we have presented the first case of DRESS syndrome due to hydroxychloroquine with a positive patch test.

CONFLICTS OF INTEREST

The authors dclare no conflict of interest.

AUTHOR CONTRIBUTIONS

Mª Araceli Castro Jiménez: Conceptualization; data curation; resources; software; supervision; writing‐original draft; writing‐review and editing. Nuria Navarrete Navarrete: Conceptualization; data curation; supervision. Alejandro Raul Gratacos Gomez: Writing‐review and editing. Fernando Florido López: Conceptualization; data curation; software. Rosa Garcia Rodriguez: Writing‐original draft; writing‐review and editing. Gomez Elisa: Conceptualization; project administration; supervision; validation; writing‐original draft; writing‐review and editing.
  7 in total

1.  Multiple Drug Hypersensitivity Syndrome to Antituberculosis Drugs: A Case Report.

Authors:  L Carneiro-Leão; I Gomes; C Freitas; M Costa E Silva; R Viseu; J Cernadas
Journal:  J Investig Allergol Clin Immunol       Date:  2019-09-18       Impact factor: 4.333

Review 2.  Spanish Guidelines for Diagnosis, Management, Treatment, and Prevention of DRESS Syndrome.

Authors:  R Cabañas; E Ramírez; E Sendagorta; R Alamar; R Barranco; N Blanca-López; I Doña; J Fernández; I Garcia-Nunez; J García-Samaniego; R Lopez-Rico; E Marín-Serrano; C Mérida; M Moya; N R Ortega-Rodríguez; B Rivas Becerra; P Rojas-Perez-Ezquerra; M J Sánchez-González; C Vega-Cabrera; C Vila-Albelda; T Bellón
Journal:  J Investig Allergol Clin Immunol       Date:  2020-01-14       Impact factor: 4.333

3.  Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.

Authors:  Mauro Grandolfo; Paolo Romita; Domenico Bonamonte; Gerardo Cazzato; Katharina Hansel; Luca Stingeni; Claudio Conforti; Roberta Giuffrida; Caterina Foti
Journal:  Dermatol Ther       Date:  2020-05-22       Impact factor: 2.851

4.  Hydroxychloroquine-induced DRESS syndrome.

Authors:  Alessandro Volpe; Antonio Marchetta; Paola Caramaschi; Domenico Biasi; Lisa Maria Bambara; Guido Arcaro
Journal:  Clin Rheumatol       Date:  2007-10-20       Impact factor: 3.650

5.  Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.

Authors:  Pahnwat Tonya Taweesedt; Charles W Nordstrom; Jessica Stoeckel; Igor Dumic
Journal:  Biomed Res Int       Date:  2019-09-24       Impact factor: 3.411

Review 6.  Of chloroquine and COVID-19.

Authors:  Franck Touret; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2020-03-05       Impact factor: 5.970

7.  First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.

Authors:  Araceli Castro Jiménez; Nuria Navarrete Navarrete; Alejandro R Gratacós Gómez; Fernando Florido López; Rosa García Rodríguez; Elisa Gómez Torrijos
Journal:  Contact Dermatitis       Date:  2020-07-28       Impact factor: 6.600

  7 in total
  5 in total

Review 1.  Severe and life-threatening COVID-19-related mucocutaneous eruptions: A systematic review.

Authors:  Farzaneh Mashayekhi; Farnoosh Seirafianpour; Arash Pour Mohammad; Azadeh Goodarzi
Journal:  Int J Clin Pract       Date:  2021-09-28       Impact factor: 3.149

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 3.  Safety profile of COVID-19 drugs in a real clinical setting.

Authors:  Mei Nee Chiu; Maitry Bhardwaj; Sangeeta Pilkhwal Sah
Journal:  Eur J Clin Pharmacol       Date:  2022-01-28       Impact factor: 3.064

4.  First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.

Authors:  Araceli Castro Jiménez; Nuria Navarrete Navarrete; Alejandro R Gratacós Gómez; Fernando Florido López; Rosa García Rodríguez; Elisa Gómez Torrijos
Journal:  Contact Dermatitis       Date:  2020-07-28       Impact factor: 6.600

5.  A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients.

Authors:  Niloufar Najar Nobari; Farnoosh Seirafianpour; Farzaneh Mashayekhi; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-12-26       Impact factor: 3.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.